Application of the multi-disciplinary treatment-based continuous pharmaceutical care system in patients undergoing anti-infection treatment
- VernacularTitle:多学科协作诊疗持续药学监护系统在抗感染治疗患者中的应用
- Author:
Rui TAN
1
;
Tingting ZOU
1
;
Wei SUN
2
;
Libo PENG
3
;
Jinghui GOU
4
Author Information
1. Dept. of Pharmacy，Banan Hospital Affiliated to Chongqing Medical University，Chongqing 401320，China
2. Dept. of Infectious Hepatology，Banan Hospital Affiliated to Chongqing Medical University，Chongqing 401320，China
3. Dept. of Critical Care Medicine，Banan Hospital Affiliated to Chongqing Medical University，Chongqing 401320，China
4. Dept. of Pharmacy，the Third Affiliated Hospital of Chongqing Medical University，Chongqing 401120，China
- Publication Type:Journal Article
- Keywords:
multi-disciplinary treatment;
continuous pharmaceutical care system;
pharmaceutical service;
antibacterial drug
- From:
China Pharmacy
2024;35(23):2936-2940
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the application effects of the multi-disciplinary treatment （MDT）-based continuous pharmaceutical care system in patients undergoing anti-infection treatment. METHODS This research team innovatively developed an MDT continuous pharmaceutical care system， which was applied to cases of anti-infection treatment following MDT due to infection， aiming to innovate the continuous medication supervision model. A retrospective analysis method was used to collect data from 150 patients in the intensive care unit who underwent conventional anti-infection MDT consultations from January to October 2021 in Banan Hospital Affiliated to Chongqing Medical University， serving as the control group， and 130 patients in the intensive care unit who were under the MDT continuous pharmaceutical care system from January to October 2022 were selected as the intervention group. The general information of the patients， the information continuous tracking management， the outcomes of anti- infection treatment， adverse drug reactions， antibacterial drug management indicators， and the degree of satisfaction of relevant medical staff with the clinical pharmacists’ pharmaceutical services were compared between the two groups. RESULTS Comparison of general information between the two groups showed no statistically significant differences （P＞0.05）. The proportion of continuous tracking management in the intervention group was significantly higher than in the control group （P＜0.01）， and the differences in the initiators and reasons for continuous tracking management between the two groups were statistically significant （P＜0.05）. The intervention group had better outcomes in anti-infection treatment compared to the control group （P＜0.05）. The antibacterial drug management indicators （total length of hospital stay， duration of antibacterial drug use， total drug costs， and amount of antibacterial drugs used） in the intervention group were significantly lower than in the control group， while overall degree of satisfaction among medical staff was significantly higher in the intervention group than in the control group （P＜0.05）. No statistically significant differences were found in adverse reaction occurrence and antibacterial drug costs between the two groups （P＞0.05）. CONCLUSIONS The application of this system in patients who underwent anti-infection treatment after MDT can achieve continuous multi-disciplinary tracking management with clinical pharmacists at the core， which is beneficial for promoting the follow-up efficiency of the MDT team， raising the quality of clinical pharmacists’ pharmaceutical services， strengthening treatment outcomes， and promoting the rational use of antibacterial drugs in clinical practice.
